SCIP Study
Research type
Research Study
Full title
Screening for Chemotherapy Induced Peripheral neuropathy; determining the effectiveness of an early identification screening programme (SCIP study)
IRAS ID
317770
Contact name
Kelly Davies
Contact email
Duration of Study in the UK
1 years, 5 months, 30 days
Research summary
Advances in treatment have led to increased survival rates in paediatric oncology. However, side-effects may develop secondary to treatment, including chemotherapy induced peripheral neuropathy (CIPN).
CIPN is any injury, inflammation or degeneration of peripheral nerves due to chemotherapy. Signs and symptoms include: pain, muscle weakness, sensory (e.g. pins and needles), and autonomic (e.g. constipation). Progressive weakness and pain can lead to walking problems.
Treatment of CIPN to date has been limited; current options include analgesia, and dose reduction. Emerging evidence supports physical activity interventions for rehabilitation of physical problems caused by CIPN.
Screening tools for CIPN now exist, and early identification and therapy intervention may benefit children at high risk of CIPN, but this needs formal examination.
This study will examine the feasibility of conducting a study to examine the effectiveness of a CIPN screening programme, to determine if early identification of CIPN impacts on physical outcomes for children with cancer. Feasibility will include the number of children identified/recruited, and feasibility of screening/outcome measures.
This feasibility study will inform the development of a full trial which aims to examine the effectiveness of a CIPN screening programme to determine if early identification of CIPN can improve physical outcomes for children with cancer.
Children (4-<18 years) at high risk for CIPN will be eligible to participate. Following informed consent children will be randomised to either usual care (where action is taken once CIPN is diagnosed by oncology team) or a screening (early identification) programme.
The screening programme will consist of 6 screening time points between diagnosis and 6-months into chemotherapy treatment.
Any children from either usual care screening groups identified with CIPN will access routinely available care for CIPN (e.g., dose modification, therapies and analgesia).
Both groups of children will be assessed using physical function outcomes and parent/child reported outcome measure at the same timepoints (diagnosis, 6-, and 12-months).REC name
North West - Liverpool Central Research Ethics Committee
REC reference
23/NW/0094
Date of REC Opinion
19 May 2023
REC opinion
Further Information Favourable Opinion